In our in vitro study data, the anti-proliferative effects of HER2-targeted agents in HER2-amplified BTC cells were comparable to those of previous studies using HER2-positive gastric or breast cancer cell lines. The gene discussed is ERBB2; the disease is breast carcinoma.